Market attractiveness remains robust as aging populations and expanding oncology indications drive a CAGR above 7% through 2032. The shift toward hypofractionated regimens and AI‑enabled adaptive planning expands the addressable base beyond traditional radiotherapy centers. Competitive intensity is moderate; a handful of legacy vendors (Varian, Elekta) dominate, yet nimble software‑only entrants are gaining traction through cloud platforms and subscription models, intensifying price pressure. Long‑term outlook is positive, underpinned by reimbursement reforms that reward outcomes and by increasing adoption of MR‑guided and proton therapies that require sophisticated planning suites. Innovation landscape is vibrant, with AI‑based contouring, real‑time dose‑recalculation, and digital twin simulations moving from pilot to commercial rollout. Demand–supply balance is currently tight; hospitals face capacity constraints while vendors accelerate product pipelines, creating a brief shortage of skilled implementation resources. Key risk factors include regulatory delays for AI algorithms, cybersecurity threats, and potential consolidation that could limit customer choice. Overall, the Radiation Treatment Planning Solutions market outlook signals sustained growth for investors and providers alike.